Ryaltris™ (olopatadine/mometasone furoate monohydrate) – New drug approval
On January 14, 2022, Glenmark Pharmaceuticals announced the FDA approval of Ryaltris (olopatadine/mometasone furoate monohydrate), for the treatment of symptoms of seasonal allergic rhinitis in adult and pediatric patients 12 years of age and older.
Top